Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — AD/PD 2026, Copenhagen
27 slides from Anavex Life Sciences's conference presentation, Mar 21, 2026
Slide 1: Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine
Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine with Long-term Time Saved AD/PDTM 2026, Copenhagen March 21st, 2026 Authors: Timo Grimmer [1], Nell Rebowe [2], David Gould [2], Juan Carlos Lopez-Talavera [2], William R Chezem [2], Kun Jin [2], Wo
Slide 2: Disclosures
Disclosures Dr. Grimmer received consulting fees from Acumen, Advantage Ther, Alector, Anavex, Biogen, BMS, Cogthera, Eisai, Eli Lilly, Functional Neuromod., Grifols, Janssen-Cilag, Neurimmune, Noselab, Novo Nordisk, Owkin, Roche Pharma, and UCB; lecture fees from Anavex, Cogthera, Eisai, Eli Lilly,
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,
Slide 4: Novel Upstream Precision Medicine Approach with Oral Blarcamesine in Early Alzheimer's Disease
Novel Upstream Precision Medicine Approach with Oral Blarcamesine in Early Alzheimer’s Disease
Slide 5: Alzheimer's Disease Progression
Alzheimer's Disease Progression Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer’s disease 1,2 Impaired Autophagy • Lysosomal and Synaptic Dysfunction Amyloid Beta Accumulation • APP Processing Tau Tangles • Micr
Slide 6: Autophagy: An Upstream Therapeutic Intervention in Alzheimer's Disease
Autophagy: An Upstream Therapeutic Intervention in Alzheimer’s Disease Neural autophagy weakens with aging, and ‘clean-up’ diminishes further in patients with neurodegenerative diseases1,2,3 Oral blarcamesine acts as a re-activator of neural autophagy 1. Gómez, O et al. “Autophagy and Glycative Stre
Slide 7: ATTENTION-AD Phase IIb/III Alzheimer's Disease Trial
ATTENTION-AD ANAVEX®2-73-AD-EP-004 Phase IIb/III Alzheimer's Disease Trial Global, multicenter, OLE trial (combined 192 Weeks) following randomized, double-blind, placebo-controlled, parallel group, 48-week trial evaluating oral once daily Blarcamesine Solid trial design produced reliable and meanin
Slide 8: Blarcamesine Clinically Meaningful Improvements On Top Of Standard Of Care
Blarcamesine Clinically Meaningful Improvements On Top Of Standard Of Care1 Blarcamesine significantly slowed patient-relevant cognitive decline in Phase IIb/III trial 2: • Significantly slowed clinical progression by 36.3% at week 48 as well as the prespecified patient group ABCLEAR1 (~70% of popul
Slide 9: Unprecedented Blarcamesine Effect Size Over Placebo in Large Specific Genetic Population
Unprecedented Blarcamesine Effect Size Over Placebo in Large Specific Genetic Population ADAS-Cog13 LS Mean Difference at Week 48 ADCS-ADL LS Mean Difference at Week 48 CDR-SB LS Mean Difference at Week 48 -5.0 4.5 -1.6 -4.5 4 -1.4 -4.0 3.5 -1.2 Increased Treatment Effect -3.5 3 -1.0 -3.0 2.5 -2.5 -
Slide 10: Blarcamesine's Potential to Match Barely Detectable Prodromal Alzheimer's Disease Decline
Blarcamesine’s Potential to Match Barely Detectable Prodromal Alzheimer’s Disease Decline • Cognitive outcomes observed in the oral blarcamesine 30mg Precision Medicine ABCLEAR3 cohort, similar to referenced barely detectable prodromal AD decline1,2 • Strong treatment effect despite greater AD basel
Slide 11: Patient-Oriented Benefit: Self-Assessed Quality Of Life (QoL-AD)
Patient-Oriented Benefit: Self-Assessed Quality Of Life (QoL-AD) for Individuals with Alzheimer's Disease QoL-AD: What it measures: Physical health: Overall physical well-being. Energy: Level of energy and vitality. Mood: Emotional state and feelings. Living situation: Satisfaction with where the pe
Slide 12: Improvement in Self-Assessed QoL-AD with Blarcamesine in Precision Medicine Cohorts
Improvement in Self-Assessed QoL-AD Above Baseline with Blarcamesine Increases in the Precision Medicine Cohorts Our Values ITT = Intent-to-Treat population (100% population), all available data points ABCLEAR1 = Alzheimer’s Blarcamesine Cognition Efficacy and Resilience gene variant non-carrier pop
Slide 13: Phase IIb/III Trial in Early Alzheimer's Disease: Safety
ANAVEX®2-73-AD-004 Program Phase IIb/III Trial in Early Alzheimer's Disease Safety
Slide 14: Blarcamesine's Improved CNS Tolerability Over Time
Blarcamesine’s Improved CNS Tolerability Over Time: Adverse Events (AEs) Titration vs Maintenance 1 • CNS AEs (dizziness, confusional state, balance disorder, somnolence) were among the more commonly observed tolerability findings in the AD-004/AD-EP-004 studies • Mostly mild or moderate (Grade 1 or
Slide 15: Earlier Treatment Initiation with Continued Long-term Beneficial Therapeutic Effect
Blarcamesine: Earlier Treatment Initiation with Continued Long-term Beneficial Therapeutic Effect
Slide 16: ATTENTION-AD AD-004 OLE Phase IIb/III Early Alzheimer's Disease
ATTENTION-AD AD-004 OLE Phase IIb/III Early Alzheimer's Disease Global, multicenter, randomized, Open-Label-Extension (OLE), 96/144-week trial evaluating Blarcamesine (ANAVEX®2-73) once-daily oral capsules, following placebo-controlled 48-week trial1 ‘Continued Blarcamesine Blarcamesine blarcamesine
Slide 17: Significant Therapeutic Benefit of Blarcamesine Compared to ADNI Control Group over 144 Weeks
Significant Therapeutic Benefit of Blarcamesine Compared to ADNI Control Group over 144 Weeks Changes in ADAS-Cog13 AD-004/AD-EP-004 with ADNI Matched Control Clinical worsening Mean +/- SE of Change from Baseline ADAS-Cog13 Total Score DB/OLE ITT Population and Alzheimer’s Disease Neuroimaging Init
Slide 18: Extending the Dignity of Aging
Extending the Dignity of Aging Extended Time Saved1: • Patient-relevant outcome • Providing sustained patient benefit by maintaining functionality and independence 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI control group after 144 weeks (33.1 months) of treatment 1.
Slide 19: Convenience of Blarcamesine in Early Alzheimer's Disease
Convenience of Blarcamesine in Early Alzheimer’s Disease
Slide 20: Patients and Caregivers: Strong Preference for Oral Treatment
Patients and Caregivers: Strong Preference for Oral Treatment Preference for oral dosage form of Evaluation of the accessibility of oral disease modifying treatments (DMTs) treatment as ‘very convenient' 100% 100% 84.9% 89% % of surveyed patients and caregivers1 agree European patients and caregiver
Slide 21: Patients and Families Continue to be the Center and Focus
Patients and Families Continue to be the Center and Focus Advantage for patient • Allowing direct access to new oral treatment • Focus on individual patient preference Advantage for family • Less stress for caregivers and less financial strain • No impact on own work schedule Advantage for physician
Slide 22: Blarcamesine: Efficacy Confirmed with Surrogate Biomarker Data
Blarcamesine: Efficacy Confirmed with Surrogate Biomarker Data
Slide 23: Brain Volume Changes (Atrophy) Biomarker in Alzheimer's Disease
Brain Volume Changes (Atrophy) Biomarker: Part of the Biological and Clinical Changes in Alzheimer’s Disease1 Structural MRI biomarker: • Shrinkage and cortical atrophy • Progresses steadily as neurons are lost • Reflect irreversible neurodegeneration • Continues worsening into dementia stages 1. Ja
Slide 24: Reductions in Brain Atrophy with Blarcamesine Treatment
Reductions in Brain Atrophy with Blarcamesine Treatment Volumetric MRI scans of the brain at 48 weeks of treatment show significant slowing of atrophy in several key regions of the brain Whole Brain Total Grey Matter Temporal Lobe 0.0% 0.0% ** 0.0% Change from baseline brain volume (%) Change from b
Slide 25: Consistent Correlation of Atrophy Biomarker with Primary and Secondary Clinical Endpoints
Consistent Correlation of Atrophy Biomarker with Primary and Secondary Clinical Endpoints Correlation of Biomarker with Clinical Endpoints: • Association between regional brain volume changes and clinical progression across primary and secondary endpoints (ADAS-Cog13, ADCS-ADL and CDR-SB) was evalua
Slide 26: Acknowledgements
Acknowledgements Most of all, we share grateful acknowledgement of the contribution by participating Alzheimer’s disease patients and their caregivers. —Principal Investigators, Clinical Sites’ Study Staff, Data Safety Review Committee, and Anavex Scientific Advisory Board 26
Slide 27: Contact Us
Contact Us Corporate Office Shareholder & Media Relations Anavex Life Sciences Corp. ir@anavex.com 630 5th Avenue, 20th floor www.anavex.com New York, NY 10111 NASDAQ: AVXL 1-844-689-3939